Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer
Brief Summary: The primary objective of the study is to assess the progression-free survival (PFS) of oral veliparib in combination with TMZ or in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in subjects with BRCA1 or BRCA2 mutation and locally recurrent or metastatic breast cancer.


Options:
A: Arm Label: Veliparib with Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Veliparib, Drug: Temozolomide | Arm Label: Placebo with Carboplatin and Paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Carboplatin, Drug: Paclitaxel | Arm Label: Veliparib with Carboplatin and Paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: Veliparib, Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo with Carboplatin and Paclitaxel | Intervention Type: DRUG; Name: Veliparib; Assigned to Arm(s): Veliparib with Carboplatin and Paclitaxel, Veliparib with Temozolomide | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Placebo with Carboplatin and Paclitaxel, Veliparib with Carboplatin and Paclitaxel | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Veliparib with Temozolomide | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo with Carboplatin and Paclitaxel, Veliparib with Carboplatin and Paclitaxel
B: Arm Label: Atezolizumab Plus Nab-Paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Drug: Nab-Paclitaxel | Arm Label: Placebo Plus Nab-Paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nab-Paclitaxel, Drug: Placebo | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody; Assigned to Arm(s): Atezolizumab Plus Nab-Paclitaxel | Intervention Type: DRUG; Name: Nab-Paclitaxel; Assigned to Arm(s): Atezolizumab Plus Nab-Paclitaxel, Placebo Plus Nab-Paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Plus Nab-Paclitaxel
C: Arm Label: Arm G/C; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine/carboplatin | Arm Label: Arm G/C/I; Type: EXPERIMENTAL; Interventions: Drug: gemcitabine/carboplatin, Drug: iniparib | Intervention Type: DRUG; Name: gemcitabine/carboplatin; Assigned to Arm(s): Arm G/C, Arm G/C/I | Intervention Type: DRUG; Name: iniparib; Assigned to Arm(s): Arm G/C/I
D: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Doxorubicin, Drug: Paclitaxel, Drug: Carboplatin, Drug: Veliparib | Arm Label: Arm C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Placebo, Drug: Doxorubicin, Drug: Paclitaxel | Arm Label: Arm B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Doxorubicin, Drug: Paclitaxel, Drug: Carboplatin, Drug: Placebo | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm C | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Veliparib; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm B, Arm C

Answer: A